信達生物(01801.HK)減重藥物獲批首個長期體重控制適應症
信達生物(01801.HK)公佈,胰高血糖素(GCG)/胰高血糖素樣(月太)-1(GLP-1)雙受體激動劑信爾美(瑪仕度(月太)注射液)的新藥上市申請獲國家藥品監督管理局批準上市,用於成人肥胖或超重患者的長期體重控制。
公司指,信爾美是全球首個GCG/GLP-1雙受體激動減重藥物,其獨特的作用機制既能夠增加減重效果,又能夠直接降低內臟脂肪含量,帶來全面的代謝獲益,獲評爲2025年全球十大最受期待藥物之一(FIERCE Pharma 2025)。
信爾美是公司與禮來製藥共同推進的一款GCG/GLP-1雙受體激動劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.